What If I Don't Treat My PSA-Detected Prostate Cancer? Answers from Three Natural History Models
暂无分享,去创建一个
Eveline A M Heijnsdijk | Harry J de Koning | Lurdes Y T Inoue | Ruth Etzioni | Lurdes Y. T. Inoue | Roman Gulati | Gerrit Draisma | H. D. de Koning | Ruth Etzioni | Jeffrey Katcher | L. Inoue | E. Heijnsdijk | D. Penson | G. Draisma | A. Tsodikov | R. Gulati | David F Penson | Alex Tsodikov | Elisabeth M Wever | Jeffrey Katcher | Shih-Yuan Lee | E. Wever | Shih-Yuan Lee | Shih‐Yuan Lee
[1] Rascon. [The National Cancer Institute]. , 1953, Boletin cultural e informativo - Consejo General de Colegios Medicos de Espana.
[2] M. Stampfer,et al. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.
[3] E. Feuer,et al. Asymptomatic incidence and duration of prostate cancer. , 1998, American journal of epidemiology.
[4] E. Feuer,et al. Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. , 1999, Journal of the National Cancer Institute.
[5] Angela Mariotto,et al. Cancer Intervention and Surveillance Modeling Network (CISNET) , 2001, Journal of Investigative Medicine.
[6] Laurence R. Paquette,et al. Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. , 2002, Urology.
[7] S. Harland,et al. Survival prospects after screen‐detection of prostate cancer , 2002, BJU international.
[8] Michael M Lieber,et al. Journal Review , 2003, International Society of Hair Restoration Surgery.
[9] Harry J de Koning,et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.
[10] Lurdes Y T Inoue,et al. Combining longitudinal studies of PSA. , 2004, Biostatistics.
[11] Jaime Pujadas Oláno,et al. Natural history of early localized prostate cancer. , 2004, JAMA.
[12] James A Hanley,et al. Prostate cancer and the Will Rogers phenomenon. , 2005, Journal of the National Cancer Institute.
[13] P. Walsh,et al. Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.
[14] James A Hanley,et al. 20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.
[15] Barnett S Kramer,et al. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. , 2005, The Journal of urology.
[16] A Tsodikov,et al. A population model of prostate cancer incidence , 2006, Statistics in medicine.
[17] D. Dearnaley,et al. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival , 2006, British Journal of Cancer.
[18] H. D. de Koning,et al. Gleason score, age and screening: Modeling dedifferentiation in prostate cancer , 2006, International journal of cancer.
[19] E. Feuer,et al. Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey , 2007, Cancer.
[20] Dante diTommaso,et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline , 2008, Cancer Causes & Control.
[21] Ruth Etzioni,et al. Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence Trends , 2008, Biometrics.
[22] P. Albertsen. Predicting survival for men with clinically localized prostate cancer , 2008, Cancer.
[23] Seth Falcon,et al. Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling Approach , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.
[24] T. Wilt,et al. Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer , 2008, Annals of Internal Medicine.
[25] Peter Müller,et al. Modeling Disease Progression With Longitudinal Markers , 2008, Journal of the American Statistical Association.
[26] J. Cuzick,et al. Nomogram incorporating PSA level to predict cancer‐specific survival for men with clinically localized prostate cancer managed without curative intent , 2008, Cancer.
[27] A. Tsodikov,et al. Stage‐specific cancer incidence: An artificially mixed multinomial logit model , 2009, Statistics in medicine.
[28] B. G. Blijenberg,et al. Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.
[29] David Chia,et al. Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.
[30] A. Kibel. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context , 2009 .
[31] Ruth Etzioni,et al. Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. , 2010, Biostatistics.
[32] H. D. de Koning,et al. Prostate-Specific Antigen Screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer–Rotterdam , 2010, Journal of the National Cancer Institute.
[33] A. Wein,et al. Campbell-Walsh Urology , 2011 .
[34] I. Thompson,et al. Epidemiology, Etiology, and Prevention of Prostate Cancer , 2012 .